Abstract 11954: Left Atrial Appendage Closure versus Direct Oral Anticoagulants in Non-Valvular Atrial Fibrillation: An Updated Systematic Review and Meta-Analysis
Abstract
Background: Direct oral anticoagulants (DOACs) are the standard strategy for stroke prevention in non-valvular atrial fibrillation (AF), but long-term anticoagulation may be unsuitable for some patients because of bleeding risk or intolerance. Left atrial appendage closure (LAAC) has emerged as an alternative approach; however, comparative data between LAAC and DOACs remain limited. We performed an updated systematic review and meta-analysis incorporating recently reported randomized trial data to compare clinical outcomes between LAAC and DOAC therapy. Methods: PubMed, Embase, Cochrane Library, and major cardiovascular meeting databases were systematically searched for studies comparing LAAC with DOACs in patients with non-valvular AF. Randomized and observational studies reporting clinical outcomes of interest were included. Risk ratios (RRs) with 95% confidence intervals (CIs) were pooled using random-effects models. Primary outcomes included all-cause mortality, major adverse cardiovascular events (MACE), clinically relevant bleeding, stroke/transient ischemic attack (TIA), systemic embolism, and cardiovascular death. Results: Nineteen studies, including five randomized trials and fourteen observational cohorts, comprising more than 25,000 patient-years of follow-up were analyzed. Compared with DOAC therapy, LAAC was associated with lower all-cause mortality (RR 0.67, 95% CI 0.56-0.79; p<0.0001), reduced MACE (RR 0.73, 95% CI 0.57-0.94; p=0.01), and lower clinically relevant bleeding (RR 0.74, 95% CI 0.65-0.83; p<0.0001). Rates of stroke/TIA (RR 0.96, 95% CI 0.83-1.12; p=0.63), systemic embolism (RR 0.95, 95% CI 0.77-1.17; p=0.62), and cardiovascular death (RR 0.90, 95% CI 0.69-1.17; p=0.43) were similar between groups. In randomized-trial-only analyses, reductions in mortality and bleeding were attenuated and no longer statistically significant. Conclusions: Among patients with non-valvular AF, LAAC was associated with lower all-cause mortality, MACE, and clinically relevant bleeding compared with DOAC therapy, while maintaining similar protection against stroke, systemic embolism, and cardiovascular death. The attenuation of benefit in randomized-trial analyses suggests that residual confounding may contribute to observed differences and highlights the need for additional adequately powered randomized studies.